CETSA® Rapid assay development Is Your Compound Actually Therapeutic? CETSA® (Cellular Thermal Shift Assay) The patented Cellular Thermal Shift Assay (CETSA®) gives a quantitative measure of target engagement and a true physiologically relevant readout of affinity, adding real value to existing efficacy assays. CETSA provides a measure for target engagement, which will help you make the right decisions faster and improve the quality in your discovery programs. Latest news CEO describes CETSA Pelago Bioscience CEO describes the benefits of CETSA Read more AstraZeneca Pelago enters into a new collaboration with AstraZeneca Read more [Webinar] Is Your Compound Therapeutic? Did you miss our webinar? Read more About us Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs. The company moved to purpose built laboratories at its current location in 2016 and continues to expand. Meet us Meet a Pelago representative at the next upcoming conference or meeting. Stockholm, Sweden - September 10-12, 2018 Nordic Life Science Days in Stockholm See more meetings coming up! Pelago Bioscience AB Banvaktsvägen 20 171 48 Solna Sweden Contact E-mail: info@pelagobio.com Follow us Website & Design by Intendit Web Agency Get a free copy of the CETSA review paper Review Article on CETSA® Name E-mail institution /Company Send